Ozempic maker Novo Nordisk gets another downgrade. The end's in sight for its duopoly status, says TD Cowen.

A broker downgrade of Novo Nordisk cites growing competitive threats that could undermine its duopoly position in diabetes and weight-loss markets. The downgrade signals downside risk to market share and could pressure the stock near-term as investors reassess growth defensibility.

Analysis

A broker downgrade of Novo Nordisk cites growing competitive threats that could undermine its duopoly position in diabetes and weight-loss markets. The downgrade signals downside risk to market share and could pressure the stock near-term as investors reassess growth defensibility.